 |
Top 73 Genome Analysis startups
Oct 12, 2024 | By Jason Kwon | 28 |
These startups are making genome analysis more quick and affordable to enable personalized medicine, identify disease risks and guide treatment decisions based on an individual's unique genetic profile.
1
Country: USA | Funding: $2B
Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
2
Country: USA | Funding: $1.9B
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
3
Country: UK | Funding: £1.1B
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
4
Country: USA | Funding: $1.4B
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
5
Country: USA | Funding: $1.1B
23andMe is the first and only genetic service available directly to you that includes reports that meet FDA standards.
23andMe is the first and only genetic service available directly to you that includes reports that meet FDA standards.
6
Country: USA | Funding: $1B
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
7
Country: USA | Funding: $925.9M
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
8
Country: USA | Funding: $603.3M
Fulcrum Therapectics to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
Fulcrum Therapectics to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
9
Country: USA | Funding: $600M
Ultima Genomics is unleashing the power of genomics at scale.
Ultima Genomics is unleashing the power of genomics at scale.
10
Country: USA | Funding: $497M
Color provides a high-quality, physician-ordered, genetic test at a low cost. We include support for physicians, as well as genetic counseling as part of every purchase. Our goal is to expand physician-supported access to genetic testing for hereditary cancer risk to every person, everywhere.
Color provides a high-quality, physician-ordered, genetic test at a low cost. We include support for physicians, as well as genetic counseling as part of every purchase. Our goal is to expand physician-supported access to genetic testing for hereditary cancer risk to every person, everywhere.
11
Country: USA | Funding: $472.6M
DNAnexus combines expertise in cloud computing and Bioinformatics to create a global network for genomic medicine.
DNAnexus combines expertise in cloud computing and Bioinformatics to create a global network for genomic medicine.
12
Country: USA | Funding: $403M
At Helix, we’re dedicated to making DNA learning accessible and actionable for everyone. It’s our mission to empower every person to improve their life through DNA. We believe in a world where everyone benefits from their biological information and is able to help all of humanity lead better lives.
At Helix, we’re dedicated to making DNA learning accessible and actionable for everyone. It’s our mission to empower every person to improve their life through DNA. We believe in a world where everyone benefits from their biological information and is able to help all of humanity lead better lives.
13
Country: USA | Funding: $369.8M
Human Longevity is the genomics-based, technology-driven company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine.
Human Longevity is the genomics-based, technology-driven company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine.
14
Country: USA | Funding: $354M
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
15
Country: USA | Funding: $337.3M
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
16
Country: USA | Funding: $286.7M
Our pioneering, flexible diagnostic instrument and disposable cartridge system is designed for decentralised laboratory, point-of–care and other near-patient settings. It provides a fast, easy-to-use and accurate affordable solution to screening for the presence of STIs and HAIs, where rapid diagnosis is essential for effective treatment and control.
Our pioneering, flexible diagnostic instrument and disposable cartridge system is designed for decentralised laboratory, point-of–care and other near-patient settings. It provides a fast, easy-to-use and accurate affordable solution to screening for the presence of STIs and HAIs, where rapid diagnosis is essential for effective treatment and control.
17
Country: Switzerland | Funding: $265.2M
Sophia Genetics aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning.
Sophia Genetics aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning.
18
Country: USA | Funding: $244.7M
Our services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Our expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.
Our services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Our expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.
19
Country: USA | Funding: $225.1M
Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human exomes and genomes. We support researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Our ACE (Accuracy and Content Enhanced) Technology supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy.
Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human exomes and genomes. We support researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Our ACE (Accuracy and Content Enhanced) Technology supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy.
20
Country: China | Funding: $200M
iCarbonX aims to build an ecosystem of digital life based on a combination of an individual’s biological, behavioral and psychological data, the Internet and artificial intelligence.
iCarbonX aims to build an ecosystem of digital life based on a combination of an individual’s biological, behavioral and psychological data, the Internet and artificial intelligence.
